.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Healthtrust
UBS
McKinsey
Queensland Health
Cantor Fitzgerald
Covington
Citi
Cerilliant
Fuji

Generated: July 23, 2017

DrugPatentWatch Database Preview

ZOFRAN Drug Profile

« Back to Dashboard

Which patents cover Zofran, and what generic Zofran alternatives are available?

Zofran is a drug marketed by Novartis Pharms Corp and Glaxosmithkline and is included in five NDAs.

The generic ingredient in ZOFRAN is ondansetron. There are twenty-eight drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the ondansetron profile page.

Summary for Tradename: ZOFRAN

Patents:0
Applicants:2
NDAs:5
Suppliers / Packagers: see list1
Bulk Api Vendors: see list77
Clinical Trials: see list76
Patent Applications: see list849
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ZOFRAN at DailyMed

Pharmacology for Tradename: ZOFRAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp
ZOFRAN
ondansetron hydrochloride
TABLET;ORAL020103-001Dec 31, 1992ABRXYesNo► Subscribe► Subscribe
Novartis Pharms Corp
ZOFRAN ODT
ondansetron
TABLET, ORALLY DISINTEGRATING;ORAL020781-001Jan 27, 1999ABRXYesNo► Subscribe► Subscribe
Novartis Pharms Corp
ZOFRAN
ondansetron hydrochloride
SOLUTION;ORAL020605-001Jan 24, 1997AARXYesYes► Subscribe► Subscribe
Novartis Pharms Corp
ZOFRAN ODT
ondansetron
TABLET, ORALLY DISINTEGRATING;ORAL020781-002Jan 27, 1999ABRXYesYes► Subscribe► Subscribe
Novartis Pharms Corp
ZOFRAN
ondansetron hydrochloride
TABLET;ORAL020103-002Dec 31, 1992ABRXYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ZOFRAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp
ZOFRAN
ondansetron hydrochloride
TABLET;ORAL020103-003Aug 27, 19995,578,628*PED► Subscribe
Novartis Pharms Corp
ZOFRAN
ondansetron hydrochloride
TABLET;ORAL020103-002Dec 31, 19924,695,578*PED► Subscribe
Novartis Pharms Corp
ZOFRAN
ondansetron hydrochloride
TABLET;ORAL020103-002Dec 31, 19924,753,789*PED► Subscribe
Novartis Pharms Corp
ZOFRAN
ondansetron hydrochloride
INJECTABLE;INJECTION020007-001Jan 4, 19914,695,578*PED► Subscribe
Novartis Pharms Corp
ZOFRAN
ondansetron hydrochloride
INJECTABLE;INJECTION020007-001Jan 4, 19915,578,628*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ZOFRAN

Drugname Dosage Strength RLD Submissiondate
ondansetron hydrochlorideOral Solution4 mg/5 mLZofran12/20/2004
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
UBS
AstraZeneca
Colorcon
Covington
McKinsey
Cerilliant
Dow
Johnson and Johnson
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot